{"id":"NCT02950155","sponsor":"Fredrik Piehl","briefTitle":"A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis","officialTitle":"A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10-16","primaryCompletion":"2021-01-30","completion":"2022-01-31","firstPosted":"2016-10-31","resultsPosted":"2024-10-26","lastUpdate":"2024-10-26"},"enrollment":47,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Myasthenia Gravis"],"interventions":[{"type":"DRUG","name":"Rituximab","otherNames":["Mabthera"]},{"type":"DRUG","name":"Sodium Chloride solution","otherNames":["Sodium Chloride"]}],"arms":[{"label":"Rituximab","type":"EXPERIMENTAL"},{"label":"Sodium Chloride solution","type":"SHAM_COMPARATOR"}],"summary":"A randomized, double-blind, placebo-controlled multicenter study evaluating the safety and efficacy of Rituximab (Mabthera®) in patients with new onset generalized myasthenia gravis (MG).","primaryOutcome":{"measure":"Percentage of Patients With Quantitative MG Score (QMG) Score ≤ 4 and a Daily Prednisolon Dose of ≤ 10mg at 16 Weeks After Administration of Study Drug/Placebo.","timeFrame":"16 weeks","effectByArm":[{"arm":"Rituximab","deltaMin":17,"sd":null},{"arm":"Sodium Chloride Solution","deltaMin":6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Sweden"]},"refs":{"pmids":["36121672"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":25},"commonTop":["Upper respiratory infection","Musculoskeletal pain","Diarrhea","Rash","Muscle cramps"]}}